CommercialCoverageLow impact
08.01.96a, olipudase alfa-rpcp (Xenpozyme®)
Independence Blue Cross·Endocrinology, Pediatrics, Internal Medicine·Pharmacy
Effective date
Mar 5, 2025
We identified it
Jun 19, 2026
Summary
A commercial insurance policy for olipudase alfa-rpcp (Xenpozyme®) has been reissued with updates. This is a pharmacy policy affecting coverage for this specific medication, which is used to treat acid sphingomyelinase deficiency (ASMD).
Action Required
By March 5, 2025: Review the updated policy at the provided URL to understand any changes to coverage criteria, prior authorization requirements, or billing procedures for olipudase alfa-rpcp (Xenpozyme®). Update any internal protocols or prior authorization workflows if this medication is prescribed at your practice.